DD298053A5 - Verfahren zum herstellen einer stabilen zubereitung eines pharmazeutischen peptides - Google Patents

Verfahren zum herstellen einer stabilen zubereitung eines pharmazeutischen peptides Download PDF

Info

Publication number: DD298053A5
Authority: DD; German Democratic Republic
Prior art keywords: peptide; thymopentin; peptides; amino acid; formulations
Prior art date: 1989-09-28

Application number

DD90344215A

Other languages

German (de)

English (en)

Inventor

Gideon Goldstein

Tapan Audhya

Original Assignee

��@��@��k��Kk��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-28

Filing date

1990-09-26

Publication date

1992-02-06

1990-09-26 Application filed by ��@��@��k��Kk�� filed Critical ��@��@��k��Kk��

1992-02-06 Publication of DD298053A5 publication Critical patent/DD298053A5/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 71
238000004519 manufacturing process Methods 0.000 title claims abstract description 7
238000002360 preparation method Methods 0.000 title claims description 10
238000000034 method Methods 0.000 claims abstract description 27
230000004071 biological effect Effects 0.000 claims abstract description 18
102400000160 Thymopentin Human genes 0.000 claims description 44
101800001703 Thymopentin Proteins 0.000 claims description 44
PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical group NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 claims description 44
229960004517 thymopentin Drugs 0.000 claims description 44
239000000203 mixture Substances 0.000 claims description 37
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 30
238000009472 formulation Methods 0.000 claims description 28
239000000243 solution Substances 0.000 claims description 26
235000001014 amino acid Nutrition 0.000 claims description 18
150000001413 amino acids Chemical class 0.000 claims description 18
239000004471 Glycine Substances 0.000 claims description 14
239000000872 buffer Substances 0.000 claims description 10
230000000087 stabilizing effect Effects 0.000 claims description 4
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
239000004475 Arginine Substances 0.000 claims description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
239000004472 Lysine Substances 0.000 claims description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
235000003704 aspartic acid Nutrition 0.000 claims description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
239000007979 citrate buffer Substances 0.000 claims description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
239000012062 aqueous buffer Substances 0.000 claims 1
102000004196 processed proteins & peptides Human genes 0.000 abstract description 25
238000003860 storage Methods 0.000 abstract description 18
239000013011 aqueous formulation Substances 0.000 abstract description 13
230000000694 effects Effects 0.000 description 12
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 10
ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
210000004027 cell Anatomy 0.000 description 6
238000012360 testing method Methods 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
238000001816 cooling Methods 0.000 description 5
238000005057 refrigeration Methods 0.000 description 4
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
239000008215 water for injection Substances 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
238000003556 assay Methods 0.000 description 3
PSWFFKRAVBDQEG-XXTQFKTOSA-N (3s)-3-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-[[1-[[(1s)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)NC(C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-XXTQFKTOSA-N 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
-1 but not limited to Proteins 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000010979 pH adjustment Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
101800003906 Substance P Proteins 0.000 description 1
108010084754 Tuftsin Proteins 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000000428 dust Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000005187 foaming Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000037041 intracellular level Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
239000013642 negative control Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000012797 qualification Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
241000894007 species Species 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000012430 stability testing Methods 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000008362 succinate buffer Substances 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000014599 transmission of virus Effects 0.000 description 1
IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
229940035670 tuftsin Drugs 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

DD90344215A 1989-09-28 1990-09-26 Verfahren zum herstellen einer stabilen zubereitung eines pharmazeutischen peptides DD298053A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US41384189A	1989-09-28	1989-09-28

Publications (1)

Publication Number	Publication Date
DD298053A5 true DD298053A5 (de)	1992-02-06

Family

ID=23638883

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD90344215A DD298053A5 (de)	1989-09-28	1990-09-26	Verfahren zum herstellen einer stabilen zubereitung eines pharmazeutischen peptides

Country Status (14)

Country	Link
EP (1)	EP0420649A3 (fr)
JP (1)	JPH04502017A (fr)
AU (1)	AU6446790A (fr)
BR (1)	BR9006934A (fr)
CA (1)	CA2026149A1 (fr)
DD (1)	DD298053A5 (fr)
HU (1)	HUT59013A (fr)
IE (1)	IE903475A1 (fr)
IL (1)	IL95663A0 (fr)
IT (1)	IT1240314B (fr)
NZ (1)	NZ235324A (fr)
PT (1)	PT95451A (fr)
WO (1)	WO1991004743A1 (fr)
ZA (1)	ZA907492B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5036050A (en) *	1989-01-12	1991-07-30	Immunobiology Research Institute, Inc.	Compositions containing thymopentin for topical treatment of skin disorders
EP0689843B1 (fr) *	1993-12-17	2003-09-10	Mochida Pharmaceutical Co., Ltd.	Compositions de thrombomodulines solubles
CA2192725C (fr)	1995-12-28	2004-04-20	Kenji Tsujihara	Derives de la camptothecine
JP5485489B2 (ja) *	2000-08-11	2014-05-07	中外製薬株式会社	抗体含有安定化製剤
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
CA2531988C (fr)	2003-08-05	2016-06-28	Novo Nordisk A/S	Nouveaux derives de l'insuline
DE202004020676U1 (de)	2004-03-10	2005-11-10	Bioceuticals Arzneimittel Ag	Erythropoietin-Flüssigformulierung
ES2371361T3 (es)	2005-12-28	2011-12-30	Novo Nordisk A/S	Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
JP5552046B2 (ja)	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	インスリン誘導体を含有する薬学的製剤
PE20110543A1 (es)	2008-08-15	2011-08-04	Ironwood Pharmaceuticals Inc	Formulacion solida oral que comprende linaclotida, cation de calcio y leucina
JP4959005B2 (ja)	2008-10-30	2012-06-20	ノボ・ノルデイスク・エー／エス	毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
KR101668502B1 (ko)	2008-11-04	2016-10-21	아스카 세이야쿠 가부시키가이샤	난포자극호르몬 함유 수성 조성물
CA2770077A1 (fr)	2009-08-06	2011-02-10	Ironwood Pharmaceuticals, Inc.	Formulations comprenant du linaclotide
AR080428A1 (es)	2010-01-20	2012-04-11	Chugai Pharmaceutical Co Ltd	Formulaciones liquidas estabilizadas contentivas de anticuerpos
UA108636C2 (xx)	2010-02-17	2015-05-25		Пептид
EP2603232B1 (fr)	2010-08-11	2019-09-25	Ironwood Pharmaceuticals, Inc.	Formulations stables de linaclotide
DK2632478T3 (da)	2010-10-27	2019-10-07	Novo Nordisk As	Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
EP2699265B1 (fr)	2011-04-20	2019-10-16	Sandoz AG	Formulations liquides pharmaceutiques stables de la protéine de fusion tnfr:fc
MX347354B (es)	2011-08-17	2017-04-24	Ironwood Pharmaceuticals Inc	Tratamientos para trastornos gastrointestinales.
US10485869B2 (en)	2011-10-18	2019-11-26	Coherus Biosciences, Inc.	Etanercept formulations stabilized with meglumine
BR112014009146A8 (pt)	2011-10-18	2017-06-20	Coherus Biosciences Inc	formulações de etanercepte estabilizadas com aminoácidos
SI2895188T1 (en)	2012-09-11	2018-05-31	Coherus Biosciences, Inc.	CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE
EP2991672A1 (fr)	2013-04-30	2016-03-09	Novo Nordisk A/S	Schéma d'administration d'un nouveau type
CN105012232B (zh) *	2015-08-14	2017-09-05	北京世桥生物制药有限公司	一种胸腺五肽注射液及其制作方法
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
US20220080023A1 (en) *	2018-12-21	2022-03-17	Arecor Limited	Novel composition
US12343383B2 (en)	2019-07-12	2025-07-01	Novo Nordisk A/S	High concentration insulin formulation
EP4159236A4 (fr)	2020-05-29	2024-08-21	Chugai Seiyaku Kabushiki Kaisha	Formulation contenant un anticorps
WO2023017537A1 (fr)	2021-08-12	2023-02-16	Celagenex Research (India) Pvt. Ltd.	Composition peptidique orale perméable au tractus gastro-intestinal à base d'huile algale

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4190646A (en) *	1975-11-11	1980-02-26	Sloan-Kettering Institute For Cancer Research	Polypeptide compositions and methods
JPS57169425A (en) *	1981-04-10	1982-10-19	Eisai Co Ltd	Composition and method for preventing adsorption of secretin
DE3262575D1 (en) *	1981-12-23	1985-04-18	Schering Corp	Stabilised interferon formulations and their preparation
EP0158487B1 (fr) *	1984-04-09	1991-08-28	Takeda Chemical Industries, Ltd.	Composition stable d'interleukine-2
US4749690A (en) *	1986-01-27	1988-06-07	Ortho Pharmaceutical Corporation	Treatment of allergy with thymopentin
US4898826A (en) *	1987-12-10	1990-02-06	Invitron Corporation	Method to solubilize tissue plasminogen activator

1990
- 1990-02-20 IT IT19421A patent/IT1240314B/it active IP Right Grant
- 1990-09-12 IL IL95663A patent/IL95663A0/xx unknown
- 1990-09-14 NZ NZ235324A patent/NZ235324A/en unknown
- 1990-09-18 BR BR909006934A patent/BR9006934A/pt unknown
- 1990-09-18 JP JP2513786A patent/JPH04502017A/ja active Pending
- 1990-09-18 HU HU907939A patent/HUT59013A/hu unknown
- 1990-09-18 WO PCT/US1990/005303 patent/WO1991004743A1/fr not_active Ceased
- 1990-09-18 AU AU64467/90A patent/AU6446790A/en not_active Abandoned
- 1990-09-19 ZA ZA907492A patent/ZA907492B/xx unknown
- 1990-09-25 CA CA002026149A patent/CA2026149A1/fr not_active Abandoned
- 1990-09-26 DD DD90344215A patent/DD298053A5/de not_active IP Right Cessation
- 1990-09-27 IE IE347590A patent/IE903475A1/en unknown
- 1990-09-27 EP EP19900310606 patent/EP0420649A3/en not_active Withdrawn
- 1990-09-27 PT PT95451A patent/PT95451A/pt not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU6446790A (en)	1991-04-28
IT9019421A0 (it)	1990-02-20
PT95451A (pt)	1991-05-22
NZ235324A (en)	1992-07-28
WO1991004743A1 (fr)	1991-04-18
IT1240314B (it)	1993-12-07
IT9019421A1 (it)	1991-03-29
IE903475A1 (en)	1991-04-10
BR9006934A (pt)	1991-10-22
IL95663A0 (en)	1991-06-30
EP0420649A3 (en)	1991-07-31
ZA907492B (en)	1991-10-30
EP0420649A2 (fr)	1991-04-03
HU907939D0 (en)	1991-08-28
CA2026149A1 (fr)	1991-03-29
HUT59013A (en)	1992-04-28
JPH04502017A (ja)	1992-04-09

Legal Events

Date	Code	Title	Description
1997-06-19	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DD298053A5 (de)	1992-02-06	Verfahren zum herstellen einer stabilen zubereitung eines pharmazeutischen peptides
DE69334134T2 (de)	2007-12-20	Wässrige Formulierung enthaltend Menschliches Wachstumshormon
DE68918853T2 (de)	1995-04-13	Formulierung von menschlichen wachstumshormonen.
DE3520228C2 (de)	1994-02-24	Wasserlösliche bioaktive Trockenfeststoffzusammensetzung, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
DE69102465T2 (de)	1995-03-02	Stabilisierte Gonadotropin enthaltende Zubereitungen.
EP1517697B1 (fr)	2012-10-10	Preparations acides d'insuline ayant une meilleure stabilite
DE69329367T3 (de)	2008-06-19	Wachstumshormon-enthaltende proteinformulierung
DE69816409T2 (de)	2004-06-09	Kristallines Parathyroidhormon
EP1648485B1 (fr)	2011-04-20	Formulation destinee a un agent pharmaceutique proteique ne contenant pas d'albumine serique humaine ajoutee (hsa)
DE69431562T2 (de)	2003-06-18	Pharmazeutische formulierungen enthaltend nervenwachstumsfaktor
DE69230672T2 (de)	2000-09-21	Gonadotropin, das pharmazeutische zusammensetzungen mit sucrose stabilisator enthält
DE69103755T2 (de)	1995-02-23	Wachstumshormonkristalle und verfahren zu deren herstellung.
DE69825137T2 (de)	2005-07-21	Liposomale Erythropoietin-Dispersion
CH693019A5 (de)	2003-01-31	Insulin-Analogon-Formulierungen.
DE69827357T2 (de)	2005-11-24	Menschliches Wachstumshormon enthaltende pharmazeutische Zusammensetzung
EP0674524A1 (fr)	1995-10-04	Preparations pharmaceutiques de g-csf lyophilisees stables
DE69919533T2 (de)	2005-09-08	Proteinhaltige arzneimittel
DE10355251A1 (de)	2005-06-23	Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
DE202014011208U1 (de)	2018-08-23	C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind
EP2451471A1 (fr)	2012-05-16	Préparations d'insuline à effet retard
DE69420872T2 (de)	2000-01-13	Hgh enthaltende pharmazeutische zubereitungen
EP0855917A1 (fr)	1998-08-05	Formes galeniques pharmaceutiques stables contenant de la parathormone
DE69313444T2 (de)	1998-01-02	IL-6 ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN stabilisiert mit einem nicht-reduzierenden Zucker
DD289470A5 (de)	1991-05-02	Verfahren zur herstellung eines arzneimittels mit einem gehalt an gamma-interferon
DE69417397T2 (de)	1999-09-09	Lösung, die igf-1 enthält